Glass beads and Ge-doped optical fibres as thermoluminescence dosimeters for small field photon dosimetry

Off-the-shelf thermoluminescent silica glass media for use in medical diagnostic dosimetry applications

In respect of radiation exposure assessments, thermoluminescent dosimeters (TLD) represent a notable and important subset of passive detector technology, gaining widespread use over a period of many decades, not least for medical applications. TLDs are available in a range of physical and chemical forms, in particular the popularity of phosphor-based commercial products arising from features that include availability down to low mm dimensions, soft-tissue equivalence in some cases, and relatively low TL fading. Novel doped silica glass TL material fabricated as fibres also offer favourable responses, recent developments in co-doping leading to their ability to also provide for diagnostic radiology applications, adding to the attractive features of being impervious to water, of good sensitivity, and generally offering wide dynamic range. Thus said, doping and fibre fabrication involve relatively high costs. Accordingly, herein exploratory investigations are made of the cost-effective colourless silica-based glass medium from which marbles are made, reduced into chip form for ease of application, examining sensitivity to dose. In particular, the study focuses on the computerised tomography clinical application regime, 80- to 140 kVp, with excellent response being shown for doses within the range 2- to 50 mGy.

Small-field output ratio determination using 6 mol% Ge-doped silica fibre dosimeters

This work investigates the suitability of locally fabricated 6 mol% Ge-doped optical fibres as dosimeters for small-field output ratio measurements. Two fabrications of fibre, cylindrical (CF) and flat (FF) fibres, were used to measure doses in small photon fields, from 4 to 15 mm. The findings were compared to those of commercial Ge-doped fibre (COMM), EBT3 film and an IBA CC01 ionization chamber. Irradiations were carried out using a 6 MV SRS photon beam operating at a dose rate of 1000 cGy min^-1, delivering a dose of 16 Gy. To minimise the possibility of the fibres failing to be exposed to the intended dose in small fields, the fibres were accommodated in a custom-made Perspex phantom. For the 4 mm cone the CF and FF measured output ratios were found to be smaller than obtained with EBT3 film by 32% and 13% respectively. Conversely, while for the 6 to 15 mm cone fields the FF output ratios were consistently greater than those obtained using EBT3 film, the CF output ratios differed from those of EBT3 film by at most 3.2%, at 6 mm, otherwise essentially agreeing with EBT3 values at the other field sizes. For the 4 to 7.5 mm cones, all output ratios obtained from Ge-doped optical fibre measurements were greater than those of IBA CC01 ionization chamber. The measured FF and CF output ratios for the 7.5 to 15 mm cones agreed with published MC estimates to within 15% and 13%, respectively. Down to 6 mm cone field, present measurements point to the potential of CF as a small-field dosimeter, its use recommended to be complemented by the use of EBT3 film for small-field dosimetry.

Feasibility of using glass-bead thermoluminescent dosimeters for radiotherapy treatment plan verification

OBJECTIVE

To investigate the feasibility of using glass beads as novel thermoluminescent dosemeters (TLDs) for radiotherapy treatment plan verification.

METHODS

Commercially available glass beads with a size of 1-mm thickness and 2-mm diameter were characterized as TLDs. Five clinical treatment plans including a conventional larynx, a conformal prostate, an intensity-modulated radiotherapy (IMRT) prostate and two stereotactic body radiation therapy (SBRT) lung plans were transferred onto a CT scan of a water-equivalent phantom (Solid Water(®), Gammex, Middleton, WI) and the dose distribution recalculated. The number of monitor units was maintained from the clinical plan and delivered accordingly. The doses determined by the glass beads were compared with those measured by a graphite-walled ionization chamber, and the respective expected doses were determined by the treatment-planning system (TPS) calculation.

RESULTS

The mean percentage difference between measured dose with the glass beads and TPS was found to be 0.3%, -0.1%, 0.4%, 1.8% and 1.7% for the conventional larynx, conformal prostate, IMRT prostate and each of the SBRT delivery techniques, respectively. The percentage difference between measured dose with the ionization chamber and glass bead was found to be -1.2%, -1.4%, -0.1%, -0.9% and 2.4% for the above-mentioned plans, respectively. The results of measured doses with the glass beads and ionization chamber in comparison with expected doses from the TPS were analysed using a two-sided paired t-test, and there was no significant difference at p < 0.05.

CONCLUSION

It is feasible to use glass-bead TLDs as dosemeters in a range of clinical plan verifications.

ADVANCES IN KNOWLEDGE

Commercial glass beads are utilized as low-cost novel TLDs for treatment-plan verification.